Published in Hum Psychopharmacol on April 01, 2009
From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can J Psychiatry (2014) 0.93
The promise and reality of pharmacogenetics in psychiatry. Psychiatr Clin North Am (2010) 0.92
Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. Obstet Gynecol (2012) 0.90
Disorders related to sexuality and gender identity in the ICD-11: revising the ICD-10 classification based on current scientific evidence, best clinical practices, and human rights considerations. World Psychiatry (2016) 0.85
Factors associated with sexual arousal, sexual sensation seeking and sexual satisfaction among female African American adolescents. Sex Health (2013) 0.84
Sprague-Dawley and Fischer female rats differ in acute effects of fluoxetine on sexual behavior. J Sex Med (2012) 0.82
Pharmacology of serotonin and female sexual behavior. Pharmacol Biochem Behav (2013) 0.81
Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. Psychiatry Res (2012) 0.80
Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry (2011) 0.78
The Sexual Acceptability of Contraception: Reviewing the Literature and Building a New Concept. J Sex Res (2016) 0.77
A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach. Psychopharmacol Bull (2010) 0.77
Sexual arousal: Sex matters. Nature (2017) 0.75
Sexual dysfunction in the United States: prevalence and predictors. JAMA (1999) 14.06
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry (2006) 3.73
Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet (1993) 3.17
Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet (1996) 2.92
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry (2001) 2.53
The relationship of 5HTT (SLC6A4) methylation and genotype on mRNA expression and liability to major depression and alcohol dependence in subjects from the Iowa Adoption Studies. Am J Med Genet B Neuropsychiatr Genet (2008) 2.44
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry (2006) 2.29
The neurobiology of sexual function. Arch Gen Psychiatry (2000) 2.07
A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci U S A (1999) 1.86
Relationship of serotonin transporter gene polymorphisms and haplotypes to mRNA transcription. Am J Med Genet B Neuropsychiatr Genet (2005) 1.78
Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry (2002) 1.58
SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther (1997) 1.54
Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord (1998) 1.47
Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother (2002) 1.44
An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett (1999) 1.25
The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull (1997) 1.18
Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord (2006) 1.14
Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther (2005) 1.12
Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques. Brain Res Mol Brain Res (1998) 1.10
Ovarian steroids and serotonin neural function. Mol Neurobiol (1998) 1.04
Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull (1997) 1.02
Structure of a variable number tandem repeat of the serotonin transporter gene and association with affective disorder. Psychiatr Genet (1996) 1.02
Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology (2006) 1.00
Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine. Neuropsychopharmacology (2008) 0.95
Female sexual dysfunction related to depression and antidepressant medications. Curr Womens Health Rep (2002) 0.94
Gonadal hormones modulate 5-hydroxytryptamine2A receptors: emphasis on the rat frontal cortex. Neuroscience (1998) 0.91
[Sexual dysfunction secondary to SSRIs. A comparative analysis in 308 patients]. Actas Luso Esp Neurol Psiquiatr Cienc Afines (1997) 0.90
Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol (2007) 0.88
Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study. Pharmacogenomics (2006) 0.86
Influence of menstrual cycle on platelet serotonin uptake site and serotonin2A receptor binding. Psychoneuroendocrinology (2004) 0.80
Physiological mechanisms of sexual dysfunction side effects associated with antidepressant medication. J Psychol (1998) 0.77
Assessment of paroxetine-induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire. Psychopharmacol Bull (1995) 0.77
A time study of cancer genetic counselors using a genetic counselor-only patient care model versus a traditional combined genetic counselor plus medical geneticist care model. J Natl Compr Canc Netw (2013) 2.00
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J Thorac Oncol (2014) 1.58
Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. Bipolar Disord (2013) 1.46
Immunohistochemistry for annexin A10 can distinguish sporadic from Lynch syndrome-associated microsatellite-unstable colorectal carcinoma. Am J Surg Pathol (2014) 1.46
Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit (2006) 1.45
Antipsychotic-induced hyperprolactinemia. Pharmacotherapy (2009) 1.40
Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol (2013) 1.33
Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry (2004) 1.30
Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet (2011) 1.19
Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res (2007) 1.17
Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev (2012) 1.08
The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol (2005) 1.05
Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res (2005) 1.03
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics (2009) 1.02
Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology (2006) 1.00
Elevated plasma succinate in PTEN, SDHB, and SDHD mutation-positive individuals. Genet Med (2012) 0.98
Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet (2005) 0.97
DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences. Epigenomics (2012) 0.94
Distinctive phenotype in 9 patients with deletion of chromosome 1q24-q25. Am J Med Genet A (2011) 0.92
Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy (2009) 0.90
Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol Bull (2007) 0.89
Prevalence of germline PTEN, BMPR1A, SMAD4, STK11, and ENG mutations in patients with moderate-load colorectal polyps. Gastroenterology (2013) 0.89
CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit (2004) 0.88
Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate? Mol Diagn Ther (2013) 0.88
Phobic anxiety in late-life in relationship to cognition and 5HTTLPR polymorphism. Psychiatr Genet (2005) 0.88
LA allelic heterozygosity of the 5HTTLPR polymorphism is associated with higher cognitive function and lower interpersonal sensitivity. Psychiatr Genet (2007) 0.86
Fats and factors: lipid profiles associate with personality factors and suicidal history in bipolar subjects. PLoS One (2012) 0.86
Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metab (2015) 0.85
Genetic variations in TGFβ1, tPA, and ACE and radiation-induced thoracic toxicities in patients with non-small-cell lung cancer. J Thorac Oncol (2013) 0.85
Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia. Hum Psychopharmacol (2011) 0.85
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders. Pharmacotherapy (2011) 0.84
The influence of cognitive impairment and behavioral dysregulation on daily functioning in the nursing home setting. Am J Psychiatry (2003) 0.84
Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry (2011) 0.83
C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit (2002) 0.83
Association of plasma ω-3 and ω-6 lipids with burden of disease measures in bipolar subjects. J Psychiatr Res (2012) 0.82
The influence of cognitive impairment and psychiatric symptoms on daily functioning in nursing facilities: a longitudinal study. Ann Clin Psychiatry (2002) 0.82
Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet (2007) 0.82
Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet (2009) 0.82
Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit (2003) 0.80
Chryptochrome 2 variants, chronicity, and seasonality of mood disorders. Psychiatr Genet (2012) 0.80
Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. Psychiatry Res (2012) 0.80
P-glycoprotein (PGP) polymorphisms and sexual dysfunction in female patients with depression and SSRI-associated sexual side effects. J Sex Marital Ther (2013) 0.80
Divergent histories of rDNA group I introns in the lichen family Physciaceae. J Mol Evol (2005) 0.79
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Res (2010) 0.78
5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol (2002) 0.78
The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit (2006) 0.78
A pilot study investigating tumor necrosis factor-α as a potential intervening variable of atypical antipsychotic-associated metabolic syndrome in bipolar disorder. Ther Drug Monit (2013) 0.77
A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach. Psychopharmacol Bull (2010) 0.77
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J Clin Psychiatry (2012) 0.76
Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics. Pharmacogenomics (2014) 0.75
Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder. Clin Schizophr Relat Psychoses (2017) 0.75
Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response. Pharmacogenomics (2004) 0.75